US2015005240A1PendingUtilityA1

Therapeutic method of treatment for inhibiting tumor development using tamm-horsfall glycoprotein (thp) as immunostimulating drug and compositions

Assignee: MASSONE RAÚL ENRIQUEPriority: Feb 9, 2012Filed: Feb 8, 2013Published: Jan 1, 2015
Est. expiryFeb 9, 2032(~5.5 yrs left)· nominal 20-yr term from priority
A61P 37/04A61P 35/00A61K 38/16A61K 38/1709Y02A50/30
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient. 
     
     
         2 . A therapeutic method of treatment for inhibiting tumor development in mammals, which comprises parenterally administering to the mammal a composition comprising an effective amount of Human Tamm-Horsfall protein, native or pegylated, and a pharmacologically acceptable excipient. 
     
     
         3 . A therapeutic method of treatment for increasing the immune innate response in mammals, which comprises parenterally administering to the mammal a composition comprising an effective amount of Human Tamm-Horsfall protein, native or pegylated, and a pharmacologically acceptable excipient. 
     
     
         4 . Use of Tamm-Horsfall glycoprotein, native or pegylated, for preparing a composition for inhibiting tumor development in mammals. 
     
     
         5 . Use of Tamm-Horsfall glycoprotein, native or pegylated, for preparing a composition for increasing the immune innate response in mammals.

Join the waitlist — get patent alerts

Track US2015005240A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.